APA (7th ed.) Citation

Yao, R., Qu, Y., Hao, Z., Xu, Y., Zhang, J., Lian, J., . . . Zhou, Y. (2026). Rationale and Trial Design of DAWNA‐FES Trial: Single‐Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [18F]FES PET/CT in Patients With HR+/HER2− Advanced Breast Cancer. Cancer Innovation, 5(3), 1. https://doi.org/10.1002/cai2.70058

Chicago Style (17th ed.) Citation

Yao, Ru, et al. "Rationale and Trial Design of DAWNA‐FES Trial: Single‐Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [18F]FES PET/CT in Patients With HR+/HER2− Advanced Breast Cancer." Cancer Innovation 5, no. 3 (2026): 1. https://doi.org/10.1002/cai2.70058.

MLA (9th ed.) Citation

Yao, Ru, et al. "Rationale and Trial Design of DAWNA‐FES Trial: Single‐Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [18F]FES PET/CT in Patients With HR+/HER2− Advanced Breast Cancer." Cancer Innovation, vol. 5, no. 3, 2026, p. 1, https://doi.org/10.1002/cai2.70058.